Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.

@article{Valassi2010ClinicalRP,
  title={Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.},
  author={Elena Valassi and Anne Klibanski and Beverly M. K. Biller},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2010},
  volume={95 3},
  pages={1025-33}
}
CONTEXT An association has been demonstrated between valvular heart disease and dopamine agonist use in patients treated for Parkinson's disease. Following these reports, concern has been raised among endocrinologists about the safety of long-term treatment with dopamine agonists in hyperprolactinemic patients. The article will summarize all currently published research regarding the possible risk of valvulopathy in hyperprolactinemic patients on dopamine agonists and provide guidance based on… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Transsphenoidal Surgery

View 8 Excerpts
Highly Influenced

Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma

Indian journal of endocrinology and metabolism • 2017
View 2 Excerpts

References

Publications referenced by this paper.
Showing 1-10 of 44 references

Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline

A Colao, M Galderisi, +7 authors G Lombardi
J Clin Endocrinol Metab • 2008
View 9 Excerpts
Highly Influenced

Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

The New England journal of medicine • 2007
View 4 Excerpts
Highly Influenced

Cabergoline-related severe restrictive mitral regurgitation.

The New England journal of medicine • 2005
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…